Skip to main content

Advertisement

SpringerLink
Log in

Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value

  • Research Article
  • Published:
Tumor Biology

Abstract

Tumor markers were studied in the sera of 883 untreated patients with primary breast cancer diagnosed between 1989 and 2007. Abnormal human epidermal growth factor receptor 2 (HER-2)/neu levels (>15 ng/mL) were found in 9.5%, carcinoembryonic antigen (CEA) in 15.9%, and cancer antigen (CA) 15.3 in 19.7% of the patients. One or more tumor markers were abnormal in 305 (34.5%) of the 883 studied patients. Significantly higher serum HER-2/neu levels were found in patients with tissue overexpression of this oncoprotein (p < 0.0001). CEA, CA 15.3, and HER-2/neu (only in those patients with tissue overexpression) serum levels were related with tumor stage (tumor size and nodal involvement) and steroid receptors (higher values in estrogen receptor-negative (ER−) tumors). Univariate analysis showed that HER-2/neu serum levels were prognostic factors in disease-free survival (DFS) and overall survival (OS) only in patients with tissue overexpression. Multivariate analysis in 834 patients show that nodal involvement, tumor size, ER, CEA, and adjuvant treatment were independent prognostic factors in DFS and OS. When only patients with HER-2/neu overexpression in tissue were studied, tumor size, nodal involvement, and tumor markers (one or another positive) were independent prognostic factors for both DFS and OS. HER-2/neu serum levels were also an independent prognostic factor, with CEA, ER, and nodes in 106 patients treated with neoadjuvant treatment. In summary, serum HER-2/neu, CEA, and CA 15.3 are useful tools in the prognostic evaluation of patients with primary breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1999. Int J Cancer. 1999;80:827–41.

    Article  CAS  PubMed  Google Scholar 

  2. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E. Cancer statistics, 2004. CA Cancer J Clin. 2003;53:4–25.

    Article  Google Scholar 

  3. Early Breast Cancer Trialist's Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials. Lancet. 1998;352:930–42.

    Article  Google Scholar 

  4. Bieglmayer C, Szepesi T, Kopp B, Hoffmann G, Petrik W, Guettuoche K, et al. CA15.3, MCA, CAM26, CAM29 are members of a polymorphic family of mucin-like glycoproteins. Tumor Biol. 1991;12:138–48.

    Article  CAS  Google Scholar 

  5. Price MR, Rye PD, Petrakou R, Murray A, et al. Summary report on the ISOBM TD-4 workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. Tumor Biol. 1998;19(1):1–20.

    Article  Google Scholar 

  6. Dnistrian AM, Schwartz MK, Greenberg EJ, Smith CA, Schwartz DC. Evaluation of CAM26, CAM29, CA15.3 and CEA as circulating tumor markers in breast cancer patients. Tumor Biol. 1991;12:1282–90.

    Article  Google Scholar 

  7. Heinze T, Schurenkamper P, Minguillon C, Lichtenegger W. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors. Anticancer Res. 1997;17:2953–4.

    CAS  PubMed  Google Scholar 

  8. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Muñoz M, et al. C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer: utility in prognosis. Anticancer Res. 1996;16:2295–300.

    CAS  PubMed  Google Scholar 

  9. Volas GH, Leitzel K, Teramoto Y, Grossberg H, Demers L, Lipton A. Serial serum c-erbB-2 levels in patients with breast carcinoma. Cancer. 1996;15(78):267–72.

    Article  Google Scholar 

  10. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer. European Group on Tumor Markers Recommendations. Tumor Biol. 2005;26:281–93.

    Article  Google Scholar 

  11. Lumachi F, Basso SM, Brandes AA, Pagano D, Ermani M. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer. Anticancer Res. 2004;24:3221–4.

    CAS  PubMed  Google Scholar 

  12. Canizares F, Sola J, Perez M, Tovar I, De Las HM, Salinas J, et al. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis. Tumour Biol. 2001;22:273–81.

    Article  CAS  PubMed  Google Scholar 

  13. Molina R, Filella X, Alicarte J, Zanon G, Pahisa J, Munoz M, et al. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer. Anticancer Res. 2003;23:1035–41.

    CAS  PubMed  Google Scholar 

  14. Gion M, Boracchi P, Dittadi R, Biganzoli E, Peloso L, Mione R, et al. Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer. 2002;38:1181–8.

    Article  CAS  PubMed  Google Scholar 

  15. Duffy MJ, Duggan C, Keane R, Hill AD, McDermott E, Crown J, et al. High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem. 2004;50:559–63.

    Article  CAS  PubMed  Google Scholar 

  16. Olayioye MA, Neve RM, Lane HA, Hynes NE. The erbB signalling network: receptor heterodimerization in development and cancer. EMBO J. 2000;19:3159–67.

    Article  CAS  PubMed  Google Scholar 

  17. Ross JS, Fletcher JA. HER-2/neu (C-erbB-2) gene and protein in breast cancer. Am J Clin Pathol. 1999;112:53–67.

    Google Scholar 

  18. Potter CR, van Doele S, van de Vijver MJ, Pauwells C, Maertens G, de Boever J, et al. The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues. Histopathology. 1989;15:351–62.

    Article  PubMed  Google Scholar 

  19. Slamon D, Pegram M. Rationale for Trastuzumab (Herceptin) in adjuvant breast cancer trials. Sem Oncol. 2001;28:13–9.

    Article  CAS  Google Scholar 

  20. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287–312.

    Article  CAS  PubMed  Google Scholar 

  21. Harries M, Smith I. The development and clinical use of Trastuzumab. Endocr Relat Canc. 2002;9:75–85.

    Article  CAS  Google Scholar 

  22. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al. The HER-2/neu gene and protein in breast cancer 2003; biomarker and target of therapy. Oncologist. 2003;8:307–25.

    Article  CAS  PubMed  Google Scholar 

  23. Molina R, Jo J, Filella X, Bruix J, Castells A, Hague M, et al. Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases. Tumor Biol. 1997;18:188–96.

    Article  CAS  Google Scholar 

  24. Schwarz MK, Smith C, Schwartz DC, Dnistrian A, Neiman I. Monitoring therapy by serum HER-2/neu. Int J Biol Markers. 2000;15:324–9.

    Google Scholar 

  25. Wu JT, Astgill ME, Zhang P. Detection of the extracellular domain of c-erbB-2 oncoprotein in sera from patients with various carcinomas: correlation with tumor markers. J Clin Lab Anal. 1993;7:31–40.

    Article  CAS  PubMed  Google Scholar 

  26. Cook GB, Neamann IB, Goldblatt JL, Cambetas DR, Hussain M, Luftner D, et al. Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. Anticancer Res. 2001;21:1465–70.

    CAS  PubMed  Google Scholar 

  27. Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP. Monitoring the circulating levels of the HER-2/neu oncoprotein in Breast cancer. Clin Breast Cancer. 2004;5:105–16.

    Article  CAS  PubMed  Google Scholar 

  28. Carney WP. The emerging role of monitoring serum HER-2/neu oncoprotein levels in women with metastatic breast cancer. Lab Med. 2003;34:58–64.

    Article  Google Scholar 

  29. Fehm T, Gebauer G, Jager W. Clinical utility of serial serum c-erB-2 determinations in the follow-up of breast cancer patients. Breast Cancer Res Treat. 2002;75:97–106.

    Article  CAS  PubMed  Google Scholar 

  30. Molina R, Filella X, Zanon G, Pahisa J, Alicarte J, Muñoz M, et al. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with loco-regional breast cancer. Anticancer Res. 2003;23:1043–50.

    CAS  PubMed  Google Scholar 

  31. Dittadi R, Zancan M, Perasole A, Gion M. Evaluation of HER-2/neu in serum and tissue of primary and metastatic breast cancer patients using an automated enzyme immunoassay. Int J Biol Markers. 2001;16:255–61.

    CAS  PubMed  Google Scholar 

  32. Luftner D, Schnabel S, Possinger K. c-erbB-2 in serum of patients receiving fractionated paclitaxel chemotherapy. Int J Biol Markers. 1999;14:55–9.

    CAS  PubMed  Google Scholar 

  33. Schippinger W, Regitnit P, Bauernhofer T, et al. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer. Oncol Rep. 2004;11:1331–6.

    CAS  PubMed  Google Scholar 

  34. Molina R, Jo J, Zanon G, Filella X, Farrus B, Muñoz M, et al. Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA15.3. Br J Cancer. 1996;74:1126–31.

    CAS  PubMed  Google Scholar 

  35. Kostler WJ, Schwab B, Singer C, et al. Monitoring of serum HER-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res. 2004;10:1618–24.

    Article  PubMed  Google Scholar 

  36. Early Breast Cancer Trialist's Collaborative Group. Tamoxifen for early breast cancer: an overview of randomized trials. Lancet. 1998;351:1451–67.

    Article  Google Scholar 

  37. Mirza AN, Mirza NQ, Vlastos G, Singletary E. Prognostic factors in node-negative breast cancer. A review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg. 2002;235:10–26.

    Article  PubMed  Google Scholar 

  38. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol. 2001;19:2334–56.

    CAS  PubMed  Google Scholar 

  39. Piccart MJ, Di Leo A, Hamilton A. HER2: a predictive factor ready to use in the daily management of breast cancer patients? Eur J Cancer. 2000;36:1755–61.

    Article  CAS  PubMed  Google Scholar 

  40. Fehm T, Maimonis P, Weitz S, Teramoto Y, Katalinic A, Jager W. Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Br Cancer Res Treat. 1997;43:87–95.

    Article  CAS  Google Scholar 

  41. Fontana X, Ferrari P, Namer M, Peysson R, Salamon C, Bussiere C. C-erbB2 gene amplification and serum level of c-erb-B2 oncoprotein at primary breast cancer diagnosis. Anticancer Res. 1994;14:2099–104.

    CAS  PubMed  Google Scholar 

  42. Park BW, Oh JW, Kim JH, Park SH, Kim KS, Kim JH, et al. Preoperative CA 15.3 and CEA serum levels for breast cancer outcome. Ann Oncol. 2008;19:675–81.

    Article  PubMed  Google Scholar 

  43. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008;54:11–79.

    Article  Google Scholar 

  44. O' Hanlon DM, Kerin MJ, Koent P, Maher D, Grimes H, Given HF. An evaluation of preoperative CA15.3 measurement in primary breast carcinoma. Br J Cancer. 1995;71:1288–91.

    Google Scholar 

  45. Molina R, Jo J, Filella X, et al. C-erbB-2 oncoprotein, CEA and CA 15.3 in patients with breast cancer: prognostic value. Br Cancer Res Treat. 1998;51:109–19.

    Article  CAS  Google Scholar 

  46. Sugano K, Ushiama M, Fukutomi T, Tsuda H, Kitoh T, Ohkura H. Combined measurement of the cérbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse. Int J Cancer. 2000;89:329–36.

    Article  CAS  PubMed  Google Scholar 

  47. Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, et al. Clinical utility of serum HER/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res. 2005;7:436–43.

    Article  Google Scholar 

  48. Ebeling FC, Schmitt UM, Untch M, et al. Tumor markers CEA and CA 15.3 as prognostic factors in breast cancer. Univariate and multivariate analysis. Anticancer Res. 1999;19:2545–50.

    CAS  PubMed  Google Scholar 

  49. McLauglin R, McGrath J, Grimes H, Given HF. The prognostic value of the tumor marker CA 15.3 at initial diagnosis of patients with breast cancer. Int J Biol Markers. 2000;15:340–2.

    Google Scholar 

Download references

Conflict of interest

The authors confirm that there is not any conflict of interest including any financial, personal, or other relationships with other people or organizations that could influence their work.

Author information

Authors and Affiliations

  1. Hospital Clinic, Barcelona, Spain

    Rafael Molina, Jose M. Augé, Jose M. Escudero, Xavier Filella, Gabriel Zanon, Jaume Pahisa, Blanca Farrus, Montserrat Muñoz & Martin Velasco

Authors
  1. Rafael Molina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jose M. Augé
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jose M. Escudero
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xavier Filella
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gabriel Zanon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jaume Pahisa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Blanca Farrus
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Montserrat Muñoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Martin Velasco
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rafael Molina.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Molina, R., Augé, J.M., Escudero, J.M. et al. Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumor Biol. 31, 171–180 (2010). https://doi.org/10.1007/s13277-010-0025-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-010-0025-9

Keywords

Search

Navigation